Antibodies Contributing to Focal Epilepsy Signs and Symptoms Score

M.A.A.M. de Bruijn, A.E.M. Bastiaansen, H. Mojzisova, A. van Sonderen, R.D. Thijs, M.J.M. Majoie, R.P.W. Rouhl, M.H. van Coevorden-Hameete, J.M. de Vries, A.M. Lopetegi, B. Roozenbeek, M.W.J. Schreurs, P.A.E.S. Smitt, M.J. Titulaer*, ACES Study Group

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

17 Citations (Web of Science)

Abstract

Objective Diagnosing autoimmune encephalitis (AIE) is difficult in patients with less fulminant diseases such as epilepsy. However, recognition is important, as patients require immunotherapy. This study aims to identify antibodies in patients with focal epilepsy of unknown etiology, and to create a score to preselect patients requiring testing.Methods In this prospective, multicenter cohort study, adults with focal epilepsy of unknown etiology, without recognized AIE, were included, between December 2014 and December 2017, and followed for 1 year. Serum, and if available cerebrospinal fluid, were analyzed using different laboratory techniques. The ACES score was created using factors favoring an autoimmune etiology of seizures (AES), as determined by multivariate logistic regression. The model was externally validated and evaluated using the Concordance (C) statistic.Results We included 582 patients, with median epilepsy duration of 8 years (interquartile range = 2-18). Twenty patients (3.4%) had AES, of whom 3 had anti-leucine-rich glioma inactivated 1, 3 had anti-contactin-associated protein-like 2, 1 had anti-N-methyl-D-aspartate receptor, and 13 had anti-glutamic acid decarboxylase 65 (enzyme-linked immunosorbent assay concentrations >10,000IU/ml). Risk factors for AES were temporal magnetic resonance imaging hyperintensities (odds ratio [OR] = 255.3, 95% confidence interval [CI] = 19.6-3332.2, p < 0.0001), autoimmune diseases (OR = 13.31, 95% CI = 3.1-56.6, p = 0.0005), behavioral changes (OR 12.3, 95% CI = 3.2-49.9, p = 0.0003), autonomic symptoms (OR = 13.3, 95% CI = 3.1-56.6, p = 0.0005), cognitive symptoms (OR = 30.6, 95% CI = 2.4-382.7, p = 0.009), and speech problems (OR = 9.6, 95% CI = 2.0-46.7, p = 0.005). The internally validated C statistic was 0.95, and 0.92 in the validation cohort (n = 128). Assigning each factor 1 point, an antibodies contributing to focal epilepsy signs and symptoms (ACES) score >= 2 had a sensitivity of 100% to detect AES, and a specificity of 84.9%.Interpretation Specific signs point toward AES in focal epilepsy of unknown etiology. The ACES score (cutoff >= 2) is useful to select patients requiring antibody testing. ANN NEUROL 2021
Original languageEnglish
Pages (from-to)698-710
Number of pages13
JournalAnnals of Neurology
Volume89
Issue number4
Early online date27 Jan 2021
DOIs
Publication statusPublished - Apr 2021

Cite this